Entries by Gina Wentling

EU-ToxRisk Case Study: Developmental Toxicity Potency of Valproate Analogues in Human Pluripotent Stem Cell-Based Assay [WC-10 (2017)]

Presented at the 10th World Congress on Alternatives and Animal Use in the Life Sciences in Seattle, August 2017, by Stemina’s Associate Director of Toxicology, Jessica Palmer.

The development and use of alternative models of safety screening in place of animal models has been at the forefront of the toxicology field for over a decade; however, application of these assays in a regular setting is still poorly understood…

Prediction of Developmental Toxicity Potential Dictated by In Vivo Exposures with a Biomarker-Based Human Pluripotent Stem Cell Assay – [Teratology Society 2017 – Slides]

Presented at the Teratology Society’s 57th Annual Meeting in Denver, Colorado in June 2017 by Stemina’s Associate Director of Toxicology, Jessica Palmer.

Previous approaches for evaluating the accuracy of alternative test methods have been based on the classification of a chemical as either a positive or negative, with no other distinction…

Comparative Retrospective Analysis of In Vivo and In Vitro Developmental Toxicity Predictions [SOT 2017]

Presented at the Society of Toxicology’s Annual Meeting & ToxExpo in Baltimore, March 2017, by Stemina’s Associate Director of Toxicology, Jessica Palmer.

Development and validation of in vitro models for developmental toxicity testing is essential for reducing the number of animals used toxicity testing. These assays have the potential to reduce or replace animal use in chemical safety testing for multiple industries, as well as to support ongoing worldwide…